The abstract is read at the publisher; the summary is JClub's.
SERDs, including fulvestrant and newer oral agents like elacestrant and imlunestrant, are linked to increased antitumor immunity in breast cancer, beyond their hormone-blocking effects.
- Why it matters: Breast cancers that rely on estrogen receptor signaling need endocrine therapies, but improving outcomes also depends on understanding how treatment reshapes the tumor immune microenvironment.
- What they did: This Review summarizes the SERD clinical landscape and emerging evidence on how SERDs interact with breast cancer cells and the tumor immune microenvironment, including fulvestrant’s role in ESR1 hotspot–mutant disease.
- The result: The growing body of studies suggests SERDs can enhance antitumor immune activity, informing how next-generation SERDs may be evaluated alongside their immunologic effects.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.